Loratinib, also known as PF-06463922, is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK/ROS1 inhibitor PF-06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier.
Johnson, Ted W.; Richardson, Paul F.; Bailey, Simon; Brooun, Alexei; Burke, Benjamin J.; Collins, Michael R.; Cui, J. Jean; Deal, Judith G.; Deng, Ya-Li; Dinh, Dac; Engstrom, Lars D.; He, Mingying; Hoffman, Jacqui; Hoffman, Robert L.; Huang, Qinhua; Kania, Robert S.; Kath, John C.; Lam, Hieu; Lam, Justine L.; Le, Phuong T.; Lingardo, Laura; Liu, Wei; McTigue, Michele; Palmer, Cynthia L.; Sach, Neal W.; Smeal, Tod; Smith, Graham L.; Stewart, Albert E.; Timofeevski, Sergei; Zhu, Huichun; Zhu, Jinjiang; Zou, Helen Y.; Edwards, Martin P. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations. Journal of Medicinal Chemistry. Volume 57. Issue 11. Pages 4720-4744. Journal; Online Computer File. (2014).
Elleraas, Jeff; Ewanicki, Jason; Johnson, Ted W.; Sach, Neal W.; Collins, Michael R.; Richardson, Paul F. Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners. Angewandte Chemie, International Edition. Volume 55. Issue 11. Pages 3590-3595. Journal; Online Computer File (2016).
Li, Bryan; Barnhart, Richard W.; Hoffman, Jacqui E.; Nematalla, Asaad; Raggon, Jeffrey; Richardson, Paul; Sach, Neal; Weaver, John. Exploratory Process Development of Lorlatinib. Organic Process Research & Development. Volume 22. Issue 9. Pages 1289-1293. Journal; Online Computer File. (2018).
Anon. Process for preparation of (R)-2-(1-((2-amino-5-bromopyridin-3-yl)oxy)ethyl)-N-((5-cyano-1-methyl-1H-pyrazol-3-yl)methyl)-4-fluoro-N-methylbenzamide. IP.com Journal. Volume 19. Issue 4B. Pages 1-3. Journal; Patent. (2019).
Sha, Yu; Chen, Jiaqi; Jiang, Qingqian; Zhao, Qingmeng; Sun, Weiquan; Guo, Aofeng. Synthetic method of Lorlatinib. Assignee Shenyang Pharmaceutical University, Peop. Rep. China. CN 109232607. (2019).
